Inhaled cisplatin for stage IV lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new way to give the chemotherapy drug cisplatin—as a dry powder you inhale—for people with stage IV non-small cell lung cancer who have not yet started treatment. The goal is to see if this inhaled form is safe and effective when added to standard immunotherapy or chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have stage IV non-small cell lung cancer, confirmed by a biopsy.
- You have not yet received any treatment for stage IV lung cancer (previous chemo more than 6 months ago for earlier-stage cancer is okay).
- Your cancer can be measured on scans (RECIST 1.1) and your doctor plans to treat it with pembrolizumab alone or with carboplatin/pemetrexed or paclitaxel.
- You are in good enough health to have a performance status of 0 or 1 (able to be up and about, doing light activities).
- Your lungs work well enough: oxygen level at rest is at least 90%, and breathing tests (FEV1 and DLCO) are at least 50% of what is expected for your age and height.
- You can use a simple handheld inhaler device (like a capsule-based inhaler).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way of giving radiation (in high and low doses) together with chemotherapy and immunotherapy to treat advanced non-small cell lung cancer. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether injecting the chemotherapy drug cisplatin directly into lung tumors can help people with stage 4 lung cancer. The treatment is given during a procedure called EBUS, which uses a scope to reach the tumor.
This study tests a drug called pembrolizumab (an immunotherapy that helps your immune system fight cancer) combined with two chemotherapy drugs, without radiation. It is for people with stage III lung cancer that has not spread and has a high PD-L1 level. The goal is to see if this treatment can shrink or control the cancer better than the usual approach.
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
This trial tests a new drug combination for people with advanced non-squamous non-small cell lung cancer who have not had treatment before. It compares the new drug with a standard immunotherapy, both given with chemotherapy, to see which is more effective.
This study tests a new immunotherapy drug (cemiplimab) combined with chemotherapy for advanced squamous lung cancer. The treatment is chosen based on a blood test that measures a natural body enzyme, which may help predict how well the chemotherapy works.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.